dc.contributor.author | Martín-García, Ana | |
dc.contributor.author | López-Fernández, Teresa | |
dc.contributor.author | Mitroi, Cristina | |
dc.contributor.author | Chaparro-Muñoz, Marianela | |
dc.contributor.author | Moliner, Pedro | |
dc.contributor.author | Martín-García, Agustín C. | |
dc.contributor.author | Martínez-Monzonis, Amparo | |
dc.contributor.author | Castro, Antonio | |
dc.contributor.author | López-Sendón, José L. | |
dc.contributor.author | Sánchez, Pedro L. | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.contributor.other | Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ) | es_ES |
dc.date.accessioned | 2020-11-27T11:54:30Z | |
dc.date.available | 2020-11-27T11:54:30Z | |
dc.date.issued | 2020-02-05 | |
dc.identifier.citation | ESC Heart Failure 7 ( 2020): 763–767 | en_US |
dc.identifier.issn | 2055-5822 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/692599 | |
dc.description.abstract | Aims Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection
fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy-related cardiac dysfunction (CTRCD).
Our aim was to analyse the potential benefit of sacubitril/valsartan in patients with CTRCD.
Methods and results We performed a retrospective multicentre registry (HF-COH) in six Spanish hospitals with cardiooncology
clinics including all patients treated with sacubitril/valsartan. Demographic and clinical characteristics and laboratory
and echocardiographic data were collected. Median follow-up was 4.6 [1; 11] months. Sixty-seven patients were included (median
age was 63 ± 14 years; 64% were female, 87% had at least one cardiovascular risk factor). Median time from anti-cancer
therapy to CTRD was 41 [10; 141] months. Breast cancer (45%) and lymphoma (39%) were the most frequent neoplasm, 31%
had metastatic disease, and all patients were treated with combination antitumor therapy (70% with anthracyclines). Thirtynine
per cent of patients had received thoracic radiotherapy. Baseline median LVEF was 33 [27; 37], and 21% had atrial fibrillation.
Eighty-five per cent were on beta-blocker therapy and 76% on mineralocorticoid receptor antagonists; 90% of the
patients were symptomatic NYHA functional class ≥II. Maximal sacubitril/valsartan titration dose was achieved in 8% of patients
(50 mg b.i.d.: 60%; 100 mg b.i.d.: 32%). Sacubitril/valsartan was discontinued in four patients (6%). Baseline Nterminal
pro-B-type natriuretic peptide levels (1552 pg/mL [692; 3624] vs. 776 [339; 1458]), functional class (2.2 ± 0.6 vs.
1.6 ± 0.6), and LVEF (33% [27; 37] vs. 42 [35; 50]) improved at the end of follow-up (all P values ≤0.01). No significant statistical
differences were found in creatinine (0.9 mg/dL [0.7; 1.1] vs. 0.9 [0.7; 1.1]; P = 0.055) or potassium serum levels (4.5 mg/dL
[4.1; 4.8] vs. 4.5 [4.2; 4.8]; P = 0.5). Clinical, echocardiographic, and biochemical improvements were found regardless of the
achieved sacubitril–valsartan dose (low or medium/high doses).
Conclusions Our experience suggests that sacubitril/valsartan is well tolerated and improves echocardiographic functional
and structural parameters, N-terminal pro-B-type natriuretic peptide levels, and symptomatic status in patients with CTRCD. | en_US |
dc.description.sponsorship | This study was funded by the Instituto de Salud Carlos III,
Ministerio de Ciencia, Innovación y Universidades, Spain,
and the EU—European Regional Development Fund, by
means of a competitive call for excellence in research projects
(PIE14/00066) as well as by the Spanish Cardiovascular
Network (CIBERCV). | en_US |
dc.format.extent | 5 pag. | es_ES |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en_US |
dc.publisher | John Wiley & Sons Ltd on behalf of the European Society of Cardiology | en_US |
dc.relation.ispartof | ESC Heart Failure | en_US |
dc.rights | © 2020 The Authors | en_US |
dc.subject.other | Cancer | en_US |
dc.subject.other | Cardio-oncology | en_US |
dc.subject.other | Cardiotoxicity | en_US |
dc.subject.other | Heart failure | en_US |
dc.subject.other | Sacubitril–valsartan | en_US |
dc.title | Effectiveness of sacubitril–valsartan in cancer patients with heart failure | en_US |
dc.type | article | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | http://doi.org/10.1002/ehf2.12627 | es_ES |
dc.identifier.doi | 10.1002/ehf2.12627 | es_ES |
dc.identifier.publicationfirstpage | 763 | es_ES |
dc.identifier.publicationissue | 7 | es_ES |
dc.identifier.publicationlastpage | 767 | es_ES |
dc.relation.projectID | Gobierno de España. PIE14/00066 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
dc.rights.cc | Reconocimiento – NoComercial – SinObraDerivada | es_ES |
dc.rights.accessRights | openAccess | en |
dc.authorUAM | López-Sendón Hentschel, José Luis (262122) | |
dc.facultadUAM | Facultad de Medicina | |
dc.institutoUAM | Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ) | |